Zeptosens
Wilderswil
About Zeptosens
Zeptosens is an ultra-sensitive microarray platform for quantitative proteomic investigations. It provides microarray platforms for sensitive and quantitative protein profiling, and signaling pathway analysis by reverse protein arrays. Its products include ZeptoREADER, a microarray reader for Zeptosens planar wave guide technology; ZeptoMARK protein microarray chips and ZeptoCARRIER for various data points, which are split into arrays. The company also offers proteinarray services, including protein profiling for various samples, such as cell lines, tissues, microdissected cells, and depleted serums; and assay development. In addition, it provides training services, technical and applications support, and technical service and maintenance. The company’s products are used in various applications, including biomarker/target discovery and validation, cell-based screening, mode of action profiling, selectivity profiling, and toxicology investigation. Its customers include pharma research and development companies, biotech companies, and academic institutions. Zeptosens was founded in 2002 and is headquartered in Wilderswil, Switzerland.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1,001 – 5,000
- Total funding: $8.3M
- Funding stage: M&A
- Last round: Series B (Feb 2001)
- Website: zeptosens.com
- Phone: +41 214 30 8 00 05
Industries & Categories
Biotechnology, Health Care, Medical
Canonical: https://fsome.com/organization/zeptosens-1551079 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.